Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 0.54 |
| ▸ | ATP4A | P20648 | 6/20 | 0.53 |
| ▸ | ATP4B | P51164 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29939021 | 1.00 | APP (0.54) | APPATP4AATP4B | |
| SCHEMBL989597 | 1.00 | APP (0.54) | APPATP4AATP4B | |
| SCHEMBL5517228 | 0.85 | ATP4A (0.56) | APPATP4AATP4B | |
| SCHEMBL5517232 | 0.85 | ATP4A (0.56) | APPATP4AATP4B | |
| SCHEMBL6481943 | 0.80 | CA12 (0.52) | ATP4AATP4B | |
| SCHEMBL4009108 | 0.79 | APP (0.53) | APPATP4AATP4B | |
| SCHEMBL4164211 | 0.79 | APP (0.53) | APPATP4AATP4B | |
| SCHEMBL4164208 | 0.79 | APP (0.53) | APPATP4AATP4B | |
| SCHEMBL4009105 | 0.79 | APP (0.53) | APPATP4AATP4B | |
| SCHEMBL5513068 | 0.79 | APP (0.53) | APPATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2020-12-08 | — | — | US | disclosed |
| US-10657645-B2 | Voxel-based methods for assessing subjects using molecular magnetic resonance imaging | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-19 | — | — | US | disclosed |
| US-10650519-B2 | Voxel-based methods for assessing subjects using magnetic resonance imaging | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3231804-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2268647-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20160239968-A1 | VOXEL-BASED METHODS FOR ASSESSING SUBJECTS USING MAGNETIC RESONANCE IMAGING | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-08-18 | — | — | US | disclosed |
| US-20160239966-A1 | VOXEL-BASED METHODS FOR ASSESSING SUBJECTS USING MOLECULAR MAGNETIC RESONANCE IMAGING | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-08-18 | — | — | US | disclosed |
| US-9204835-B2 | Voxel-based methods for assessing subjects using positron emission tomography | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-12-08 | — | — | US | disclosed |
| US-20110160543-A1 | VOXEL-BASED METHODS FOR ASSESSING SUBJECTS USING POSITRON EMISSION TOMOGRAPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2011-03-10 | — | — | US | disclosed |
| EP-2268647-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7858803-B2 | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100298389-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009146388-A1 | VOXEL-BASED METHODS FOR ASSESSING SUBJECTS USING POSITRON EMISSION TOMOGRAPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009117728-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008134618-A2 | NOVEL IMAGING TRACERS FOR EARLY DETECTION AND TREATMENT OF AMYLOID PLAQUES CAUSED BY ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080267879-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20050260126-A1 | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | BF RESEARCH INSTITUTE (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | APP 1/4885ATP4A 473/4885ATP4B 858/4885 |
| US-20050260126-A1 | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | PRNP, PRPH, PCNP | APP 8/4885ATP4A 508/4885ATP4B 1525/4885 |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | APP, PSEN1, PSEN2 | APP 1/4885ATP4A 473/4885ATP4B 858/4885 |
| US-20100298389-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | APP, MAPT, PSEN1 | APP 1/4885ATP4A 1681/4885ATP4B 2108/4885 |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | APP 1/4885ATP4A 473/4885ATP4B 858/4885 |
| US-20080267879-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | APP, MAPT, PSEN1 | APP 1/4885ATP4A 1681/4885ATP4B 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.